Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from OPTN

3 Pharma Stocks to Snatch up During Market Dips

The pharmaceutical industry is undergoing rapid growth and expansion, driven by rising medical needs, favorable regulatory measures, and the implementation of pharma 4.0. Hence, investors could snatch up quality pharma stocks Bristol-Myers Squibb (BMY), Spero Therapeutics (SPRO), and OptiNose (OPTN) for steady returns during market dips. Read more.

Buy Alert: 3 Pharma Stocks Under $20 to Invest in Now

Buy Alert: 3 Pharma Stocks Under $20 to Invest in Now

With rising medicine demand and drug shortages in the U.S., pharmaceutical stocks under $20 present lucrative opportunities for investors, promising substantial returns in a ripe market. So, I think fundamentally solid pharma stocks ACADIA Pharmaceuticals (ACAD), Amneal Pharmaceuticals (AMRX), and OptiNose (OPTN), which are currently trading under $20, could be…

3 Pharma Stocks to Consider for March Gains

3 Pharma Stocks to Consider for March Gains

The pharmaceutical industry is experiencing rapid growth due to rising healthcare spending, an aging population, several technological advancements, and a favorable regulatory environment. Thus, it could be ideal to invest in quality pharma stocks Perrigo (PRGO), OptiNose (OPTN), and Teva Pharmaceutical (TEVA) for solid gains. Keep reading….

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Pharma Gems Driving Profits Now

The pharmaceutical industry is expected to expand rapidly in the coming years, driven by rising global medical needs and tech advancements. Therefore, fundamentally strong pharma stocks Kamada (KMDA), Voyager Therapeutics (VYGR) and OptiNose (OPTN) might be ideal additions to your portfolio. Read on.

The U.S. is modernizing its 39-year-old organ transplant system–just in time for the AI revolution

For the first time since the national system’s creation in 1984, multiple organizations will participate in the system’s operations.

Race, "Wokeness," and Kidney Transplant Shortages

Some conservatives are in the awkward position of resisting both policies that reduce the role of race in allocating kidneys for transplant, and those that increase it. The better way to alleviate kidney shortages is to legalize organ markets.

Biden administration plans overhaul of organ transplant system

WASHINGTON — The Health Resources and Services Administration on Wednesday unveiled plans to break up the private nonprofit overseeing the nation’s organ transplantation system, and called on Congress to help.

Tribune News Service

inkl

Read news from The Economist, FT, and more,
with one subscription

Biden administration plans overhaul of organ transplant system - Roll Call

Biden administration plans overhaul of organ transplant system - Roll Call

More than 100,000 Americans are currently waiting for an organ and an estimated 17 people die each day on the waiting list.

Looking Into OptiNose's Return On Capital Employed

Looking Into OptiNose's Return On Capital Employed

Benzinga Pro data, OptiNose (NASDAQ:OPTN) reported Q1 sales of $14.76 million. Earnings fell to a loss of $25.33 million, resulting in a 62.14% decrease from last quarter.

Optinose Stock Moves Higher On Positive Second Chronic Sinusitis Phase 3 Trial

Optinose Stock Moves Higher On Positive Second Chronic Sinusitis Phase 3 Trial

Optinose Inc (NASDAQ:OPTN) announced the statistically significant benefits of XHANCE in the ReOpen2 trial for the symptoms co-primary endpoint and the CT scan co-primary endpoint. Significant improvement was seen in patients with chronic sinusitis who did not have nasal polyps treated with both doses of XHANCE (fluticasone propionate) nasal spray compared to a…

OptiNose: Q1 Earnings Insights

OptiNose: Q1 Earnings Insights

OptiNose (NASDAQ:OPTN) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

OptiNose Earnings Preview

OptiNose Earnings Preview

OptiNose (NASDAQ:OPTN) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that OptiNose will report an earnings per share (EPS) of $-0.27.

OptiNose's Return On Capital Employed Insights

OptiNose's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q4, OptiNose's (NASDAQ:OPTN) reported sales totaled $22.51 million. Despite a 8.72% increase in earnings, the company posted a loss of $15.62 million.

Earnings Preview: OptiNose

Earnings Preview: OptiNose

OptiNose (NASDAQ:OPTN) is set to give its latest quarterly earnings report on Tuesday, 2022-03-08. Here's what investors need to know before the announcement. Analysts estimate that OptiNose will report an earnings per share (EPS) of $-0.26.

Get all your
news in one place.

100's of premium titles.
One news app.

Optinose's XHANCE Meets Primary Endpoints In Chronic Sinusitis Trial

Optinose Inc (NASDAQ: OPTN) has

1

People

Kritika SarmahHer

Mangeet Kaur BounsMangeet

Charles E Grassley

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Medical Pharmaceuticals

BristolMyers Squibb Company

ACADIA Pharmaceuticals Inc

Teva Pharmaceutical Industries Limited

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Kidney Transplant

Places

359,078 stories

Washington D.C.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play